Alliance Global Partners Maintains Buy Rating for Sensus Healthcare: Here's What You Need To Know

Alliance Global Partners has decided to maintain its Buy rating of Sensus Healthcare SRTS and lower its price target from $17.50 to $16.50.

Shares of Sensus Healthcare are trading down 39.92% over the last 24 hours, at $7.81 per share.

A move to $16.50 would account for a 111.27% increase from the current share price.

About Sensus Healthcare

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating skin cancers including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated primarily from customers in the United States.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.